Researchers report that Puerto Rican adults with type 2 diabetes in the greater Boston area who were using insulin and lived next to roads with heavy traffic had markedly increased C-reactive protein (CRP), a marker of inflammation, compared to those living in lower traffic areas. Individuals taking oral diabetes medications did not experience increases in CRP concentration.
The study (“Medication type modifies inflammatory response to traffic exposure in a population with type 2 diabetes”), published online in Environmental Pollution, builds on the research team's previous work suggesting that oral diabetes medications may provide a protective effect against inflammation for people with type 2 diabetes.
“Increases in CRP concentration [75-200%] were significantly associated with residence ≤100 m of a roadway or near multiple roadways, vs. further away, for individuals using insulin in stratified models, with consistent results in interaction models,” wrote the investigators.
“In contrast, CRP concentration did not increase for the 22% of people taking metformin and/or other oral diabetes medications who were also living in the high traffic areas,” noted Christine Rioux, Ph.D., first and corresponding author, research assistant professor in the department of public health and community medicine at Tufts University School of Medicine
Prior studies of the adverse health effects of traffic or air pollution have not considered the role that type of medication may play in relation to inflammation for people with diabetes. In a cross-sectional study published in 2011, this research team reported that medication type appeared to modify the relationship between traffic exposure and CRP concentration.
Of the 356 participants in the new study, approximately 20% lived within 100 meters of one or more roads with more than 20,000 vehicles/day. Another 20% lived within 100 to 200 meters of roads with more than 20,000 vehicles/day. Approximately 70% of the 356 participants in the study lived in Boston neighborhoods. CRP was measured at the beginning of the study and again two years later, using a high sensitivity test.
Study participants are part of a larger cohort of Puerto Ricans living in the Boston area who were found to have a high prevalence (40%) of type 2 diabetes. Of 356 study participants, 91 (26%) used insulin, 197 (55%) used only oral diabetes medication and 68 (19%) reported using no diabetes medication.
“It's important to know who is most vulnerable to the adverse effects of traffic pollution exposure for purposes of education and policy. People who live near busy roads and spend most of their time in these areas have been shown in many studies to have higher levels of inflammation, a risk factor for many cardiovascular and metabolic diseases. People on insulin appear to be even more susceptible to increases in inflammation when living in high traffic areas. People can reduce their exposure to traffic pollution by keeping windows closed during the heaviest traffic periods of the day, using air conditioners in the summer months, and avoiding heavy exercise near busy roads, especially during peak traffic times,” continued Dr. Rioux.
“This study is important because many people who live near highways may have diabetes and other serious chronic conditions. It's interesting to see that treatments for diabetes may interact with the risks associated with exposure to air pollution. While this is an intriguing finding, it is not clear why oral diabetes medications, unlike insulin, appear to be protective and it warrants additional research,” added last author Mkaya Mwamburi, M.D., Ph.D., director of the Center for Global Public Health and associate professor in the department of public health and community medicine, both at Tufts University School of Medicine.